EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2024
0mins
Should l Buy NVO?
Source: Business Insider
- Roundhill Investments Launches New ETF: Roundhill launched the world's first GLP-1 & Weight Loss ETF (OZEM) focusing on weight loss drugs like GLP-1 agonists.
- Market Potential for Weight Loss Drugs: Market for weight loss drugs could grow significantly by 2030, with OZEM investing heavily in companies like Eli Lilly and Novo Nordisk.
- Revolutionary Weight Loss Drugs: New drugs promise significant weight loss compared to traditional methods, driving demand for precision-focused exposure through ETFs like OZEM.
- ETF Details: OZEM is actively managed, priced at 0.59%, and offers specific exposure to key companies in the weight loss drug sector.
- Industry Dynamics: Despite new entrants like Hims & Hers Health offering generic versions of weight loss drugs, industry prices are expected to decline as more drugs enter the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 36.670
Low
42.00
Averages
54.67
High
70.00
Current: 36.670
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Launches New Wegovy HD for Obesity Treatment
- New Drug Launch: Novo Nordisk announced the availability of its newly approved 7.2 mg Wegovy HD in the U.S., allowing patients to access the highest dose of this popular GLP-1 medication, which is expected to significantly enhance market share.
- Pricing Strategy: Wegovy HD is priced at $399 per month, with commercial insurance customers paying as little as $25, demonstrating Novo's pricing flexibility aimed at attracting a broader patient base.
- Clinical Data Support: Backed by recent clinical trial data showing an average weight loss of 20.7% over 72 weeks for the 2.4 mg version, this provides strong scientific evidence for the new drug's market promotion, boosting confidence among doctors and patients.
- Nationwide Accessibility: Wegovy HD will be available nationwide through pharmacies and select telehealth providers, ensuring patients can conveniently access this new therapy, further solidifying Novo Nordisk's leadership position in the obesity treatment market.
See More
New Tax Year Brings Economic Challenges for UK Households
- Tax Policy Impact: The start of the 2026-27 tax year in the UK sees frozen tax thresholds and allowances, pushing many workers into higher tax brackets due to wage increases, thereby increasing household tax burdens and reducing disposable income.
- Rising Compliance Costs for SMEs: The new 'Making Tax Digital' rules require 860,000 sole traders and landlords to report income and expenses quarterly to HMRC, which is expected to raise compliance costs and add financial strain on small businesses.
- Increased Cost of Living: Households are facing rising living costs, particularly with water bills and council tax increasing, with an average council tax hike of 4.99%, exacerbating financial pressures on families amid rising energy prices due to the Middle East conflict.
- Insufficient Government Support: Although benefit payments have increased, the overall rise in living costs indicates that the government's fiscal policies have failed to alleviate economic pressures on households, potentially leading to growing dissatisfaction with the current administration.
See More
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Weight-loss Drugs in Focus: The spotlight is on weight-loss drugs, particularly GLP-1 medications like Wegovy and Zepbound, as they gain popularity.
Market Competition: Eli Lilly and Novo Nordisk are key players in the emerging "diabesity" market, indicating a competitive landscape ahead.
See More
Novo Nordisk Introduces Increased Dosage of Wegovy Injection Nationwide — Retail Analysts Consider Stock 'Significantly Undervalued'
WeGovy HD Approval: Novo has received approval for a higher dose of its WeGovy injection, which showed that 89% of participants achieved 5% or greater weight loss at 72 weeks in a recent clinical trial.
Pricing and Availability: The WeGovy HD injection will be priced at $399 per month and will be available through over 70,000 U.S. pharmacies, including Novo's own pharmacy services.
Market Competition: Novo launched its weight loss pill earlier this year to regain market share lost to competitors like Eli Lilly, which has been eroding its dominance in the weight loss medication market.
Stock Performance: Following the announcement of the WeGovy HD availability, Novo's stock saw a significant increase in retail chatter, although it remains undervalued according to some market analysts.
See More
Amazon and USPS Reach Tentative Package-Handling Agreement
- Package-Handling Agreement: Amazon and the U.S. Postal Service have reached a tentative agreement that reduces Amazon's USPS shipment cuts from two-thirds to only 20%, ensuring the Postal Service continues to handle over 1 billion packages annually, thereby stabilizing Amazon's last-mile logistics network while protecting roughly $6 billion in revenue for the Postal Service.
- Logistics Competitive Landscape: By maintaining high shipment volumes with USPS, Amazon avoids over-reliance on rivals like United Parcel Service (UPS) and FedEx, who have previously scaled back their partnerships with the e-commerce giant, thus ensuring its competitive edge in the e-commerce sector.
- Rural Infrastructure Protection: This deal allows Amazon to sustain its one-to-two-day delivery promises in low-density areas without the immediate capital expenditure required to fully replace the Postal Service's massive existing ground network, thereby securing its market share in these regions.
- Strategic Implications: The agreement not only reinforces Amazon's logistics capabilities but also reflects its strategy of relying on external partners to meet complex delivery demands while expanding its own logistics operations, showcasing its flexible market response strategy.
See More
Trump's Tough Stance on Iran Conflict as Deadline Approaches
- Diminishing Ceasefire Hopes: Trump stated that the latest ceasefire proposal is 'not good enough' and threatened large-scale U.S. attacks on Iran's power plants and bridges if the Strait of Hormuz is not reopened, escalating market anxiety ahead of the deadline.
- Rising Oil Prices: With the Strait of Hormuz still effectively closed, oil prices continue to rise, leading to a 200-point drop in Dow futures as investors grow pessimistic about the prospects of a U.S.-Iran deal, reflecting concerns over future developments.
- UMG Stock Surge: Bill Ackman's Pershing Square proposed a cash and stock deal worth approximately €55.8 billion to acquire Universal Music Group, with a per-share price of €30.4, representing nearly an 80% premium over UMG's closing price, potentially transforming UMG's market performance.
- New Partnerships for Broadcom: Broadcom announced new deals with Google and Anthropic, enhancing its AI chip production capabilities, with Anthropic's annual revenue soaring from $9 billion to $30 billion, indicating strong demand for AI infrastructure.
See More
Novo Nordisk Launches New Wegovy HD for Obesity Treatment
- New Drug Launch: Novo Nordisk announced the availability of its newly approved 7.2 mg Wegovy HD in the U.S., allowing patients to access the highest dose of this popular GLP-1 medication, which is expected to significantly enhance market share.
- Pricing Strategy: Wegovy HD is priced at $399 per month, with commercial insurance customers paying as little as $25, demonstrating Novo's pricing flexibility aimed at attracting a broader patient base.
- Clinical Data Support: Backed by recent clinical trial data showing an average weight loss of 20.7% over 72 weeks for the 2.4 mg version, this provides strong scientific evidence for the new drug's market promotion, boosting confidence among doctors and patients.
- Nationwide Accessibility: Wegovy HD will be available nationwide through pharmacies and select telehealth providers, ensuring patients can conveniently access this new therapy, further solidifying Novo Nordisk's leadership position in the obesity treatment market.
See More
New Tax Year Brings Economic Challenges for UK Households
- Tax Policy Impact: The start of the 2026-27 tax year in the UK sees frozen tax thresholds and allowances, pushing many workers into higher tax brackets due to wage increases, thereby increasing household tax burdens and reducing disposable income.
- Rising Compliance Costs for SMEs: The new 'Making Tax Digital' rules require 860,000 sole traders and landlords to report income and expenses quarterly to HMRC, which is expected to raise compliance costs and add financial strain on small businesses.
- Increased Cost of Living: Households are facing rising living costs, particularly with water bills and council tax increasing, with an average council tax hike of 4.99%, exacerbating financial pressures on families amid rising energy prices due to the Middle East conflict.
- Insufficient Government Support: Although benefit payments have increased, the overall rise in living costs indicates that the government's fiscal policies have failed to alleviate economic pressures on households, potentially leading to growing dissatisfaction with the current administration.
See More
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Weight-loss Drugs in Focus: The spotlight is on weight-loss drugs, particularly GLP-1 medications like Wegovy and Zepbound, as they gain popularity.
Market Competition: Eli Lilly and Novo Nordisk are key players in the emerging "diabesity" market, indicating a competitive landscape ahead.
See More
Novo Nordisk Introduces Increased Dosage of Wegovy Injection Nationwide — Retail Analysts Consider Stock 'Significantly Undervalued'
WeGovy HD Approval: Novo has received approval for a higher dose of its WeGovy injection, which showed that 89% of participants achieved 5% or greater weight loss at 72 weeks in a recent clinical trial.
Pricing and Availability: The WeGovy HD injection will be priced at $399 per month and will be available through over 70,000 U.S. pharmacies, including Novo's own pharmacy services.
Market Competition: Novo launched its weight loss pill earlier this year to regain market share lost to competitors like Eli Lilly, which has been eroding its dominance in the weight loss medication market.
Stock Performance: Following the announcement of the WeGovy HD availability, Novo's stock saw a significant increase in retail chatter, although it remains undervalued according to some market analysts.
See More
Amazon and USPS Reach Tentative Package-Handling Agreement
- Package-Handling Agreement: Amazon and the U.S. Postal Service have reached a tentative agreement that reduces Amazon's USPS shipment cuts from two-thirds to only 20%, ensuring the Postal Service continues to handle over 1 billion packages annually, thereby stabilizing Amazon's last-mile logistics network while protecting roughly $6 billion in revenue for the Postal Service.
- Logistics Competitive Landscape: By maintaining high shipment volumes with USPS, Amazon avoids over-reliance on rivals like United Parcel Service (UPS) and FedEx, who have previously scaled back their partnerships with the e-commerce giant, thus ensuring its competitive edge in the e-commerce sector.
- Rural Infrastructure Protection: This deal allows Amazon to sustain its one-to-two-day delivery promises in low-density areas without the immediate capital expenditure required to fully replace the Postal Service's massive existing ground network, thereby securing its market share in these regions.
- Strategic Implications: The agreement not only reinforces Amazon's logistics capabilities but also reflects its strategy of relying on external partners to meet complex delivery demands while expanding its own logistics operations, showcasing its flexible market response strategy.
See More
Trump's Tough Stance on Iran Conflict as Deadline Approaches
- Diminishing Ceasefire Hopes: Trump stated that the latest ceasefire proposal is 'not good enough' and threatened large-scale U.S. attacks on Iran's power plants and bridges if the Strait of Hormuz is not reopened, escalating market anxiety ahead of the deadline.
- Rising Oil Prices: With the Strait of Hormuz still effectively closed, oil prices continue to rise, leading to a 200-point drop in Dow futures as investors grow pessimistic about the prospects of a U.S.-Iran deal, reflecting concerns over future developments.
- UMG Stock Surge: Bill Ackman's Pershing Square proposed a cash and stock deal worth approximately €55.8 billion to acquire Universal Music Group, with a per-share price of €30.4, representing nearly an 80% premium over UMG's closing price, potentially transforming UMG's market performance.
- New Partnerships for Broadcom: Broadcom announced new deals with Google and Anthropic, enhancing its AI chip production capabilities, with Anthropic's annual revenue soaring from $9 billion to $30 billion, indicating strong demand for AI infrastructure.
See More
